Merck Announces Positive Results From Phase 3 Keynote 859 Trial Of Keytruda Plus Chemotherapy To Treat Patients With Her2 Negative Gastric Or Gej Adenocarcinoma
Merck announces positive results from phase 3 KEYNOTE-859 trial of Keytruda plus chemotherapy to treat patients with HER2-negative gastric or GEJ adenocarcinoma
Merck, known as MSD outside of the United States and Canada, announced results from the pivotal phase 3 KEYNOTE-859 trial investigating Keytruda, Merck
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!